Medicines and Healthcare products Regulatory Agency (MHRA) has urged the healthcare professionals to share their views on the consultation on 'how MHRA
communicate with healthcare professionals to improve medicines and medical devices' safety'.
Through this consultation the agency wants to review its approach to engagement with healthcare professionals to improve the safety of medicines and medical devices.
"We want to ensure that healthcare professionals are receiving actionable information and guidance on safe use of medicines and medical devices that they can take
into their working practice, providing timely advice to patients," said MHRA.
"We need to improve the way we communicate with healthcare professionals. We want to hear from you to enable us to transform how we communicate with you and how we
work together on our common goal of greater patient safety."
The Medicine and Healthcare Product Regulatory Agency (MHRA) has recalled all pholcodine-containing medicines from the UK pharmacy due to concerns of its
potential to cause a severe allergic reaction in some people having general anaesthesia for surgery.
The decision was made following the conclusion of a review of post-marketing safety data by the MHRA. The Commission on Human Medicines (CHM) has considered the
evidence of an increased risk of the very rare event of anaphylaxis when exposed to neuromuscular blocking agents (NMBA) and advised that pholcodine-containing
medicines should be withdrawn.
MHRA has advised pharmacists to consider recommending appropriate treatment alternatives for patients who present with a new dry cough or who are currently taking
pholcodine.
Royal Pharmaceutical Society (RPS) President Professor Claire Anderson said: "If you are taking a cough medicine (including tablets and syrups), check the packaging,
label or Patient Information Leaflet to see if pholcodine is a listed ingredient - if it is, and you have any questions, you can talk to your pharmacist who can
suggest a different medicine suitable for you.
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for Sabril 500 mg film-coated tablets & Sabril 500 mg
granules for oral solution.
Sanofi UK has recalled the batches of Sabril tablets and Sabril granules as a precautionary measure due to the detection of traces of tiapride in the batches of the
source material of the manufacturer for vigabatrin.
Sabril (vigabatrin) is indicated for adjunctive treatment of focal seizures with or without secondary generalisation not satisfactorily controlled with other
antiepileptics (under expert supervision) and monotherapy in the treatment of infantile spasms (West's syndrome).
All patients are advised not to discontinue Sabril tablets or Sabril granules without consulting with their prescriber. The risks of suddenly stopping medication
for seizures/epilepsy is higher than the potential risk presented by the presence of tiapride.
Sanofi UK have confirmed to DHSC that no other batches are impacted, and other stock remains available.